Clinical Trials Directory

Trials / Completed

CompletedNCT00596102

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study

Status
Completed
Phase
Study type
Observational
Enrollment
3,258 (actual)
Sponsor
Valneva Austria GmbH · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

Conditions

Interventions

TypeNameDescription
BIOLOGICALJapanese Encephalitis purified inactivated vaccineJapanese Encephalitis purified inactivated vaccine

Timeline

Start date
2005-10-01
Primary completion
2011-03-01
First posted
2008-01-16
Last updated
2014-07-30
Results posted
2014-07-30

Source: ClinicalTrials.gov record NCT00596102. Inclusion in this directory is not an endorsement.